Loss-and gain-of-function mutations in the broadly expressed gene Lrp5 affect bone formation, causing osteoporosis and high bone mass, respectively. Although Lrp5 is viewed as a Wnt coreceptor, osteoblast-specific disruption of b-Catenin does not affect bone formation. Instead, we show here that Lrp5 inhibits expression of Tph1, the rate-limiting biosynthetic enzyme for serotonin in enterochromaffin cells of the duodenum. Accordingly, decreasing serotonin blood levels normalizes bone formation and bone mass in Lrp5-deficient mice, and gut-but not osteoblast-specific Lrp5 inactivation decreases bone formation in a b-Catenin-independent manner. Moreover, gut-specific activation of Lrp5, or inactivation of Tph1, increases bone mass and prevents ovariectomy-induced bone loss. Serotonin acts on osteoblasts through the Htr1b receptor and CREB to inhibit their proliferation. By identifying duodenumderived serotonin as a hormone inhibiting bone formation in an Lrp5-dependent manner, this study broadens our understanding of bone remodeling and suggests potential therapies to increase bone mass.
INTRODUCTION
Bone remodeling, the physiological means whereby vertebrates renew their bones during adulthood, comprises two phases: resorption of preexisting mineralized bone matrix by a specialized cell type, the osteoclast, followed by de novo bone formation by another specialized cell type, the osteoblast. Over the last 15 years, molecular and genetic studies have identified numerous local and systemic regulators of this process and as a result have considerably improved our molecular understanding of both aspects of bone remodeling (Zaidi, 2007) .
One of the most intensively studied regulators of bone remodeling is LDL-receptor related protein 5 (LRP5) (Baron and Rawadi, 2007) . This interest stems from the fact that LRP5 loss-of-function mutations cause osteoporosis pseudoglioma (OPPG), a rare disease characterized by severe decreased bone formation and persistence of embryonic eye vascularization leading to low bone mass and blindness (Gong et al., 2001 ). Other, presumably activating, mutations in LRP5 cause high bone mass syndrome (Boyden et al., 2002) . That different mutations in this gene cause two bone diseases of opposite nature underscores the critical importance in the regulation of bone formation of the pathway(s) controlled by Lrp5.
Lrp5 encodes a broadly expressed cell-surface molecule sharing sequence homology with Arrow, a coreceptor for the growth factor Wingless in Drosophila (Bhanot et al., 1996) . Based on this sequence homology and, among other evidence, cellbased assays in which Lrp5 and Axin interaction is initiated by Wnt proteins, it is assumed that Lrp5 is a coreceptor for Wnt proteins, the vertebrate homologs of Wingless (Tamai et al., 2004) . As a result, OPPG and high bone mass syndrome are viewed as Wnt-related diseases (Krishnan et al., 2006) . Three observations, however, challenge this view. First, contrasting with the developmental function of most Wnt proteins, there is no overt skeletal defect in Lrp5 À/À embryos. Second, gain-of-function mutations in Lrp5 do not cause bone tumors as activation of Wnt signaling does in other organs (Moon et al., 2004) . Third and more importantly, osteoblast-specific loss-and gainof-function mutations in b-Catenin (b-Cat), the molecular node of canonical Wnt signaling, do not affect either bone formation or expression of genes dysregulated upon Lrp5 inactivation . Taken individually, none of these observations rules out that Lrp5 functions as a Wnt coreceptor to regulate bone formation. However, when considered together, we viewed them as an incentive to search for additional/other mechanisms of action of this gene in osteoblasts.
Serotonin is a bioamine generated in brainstem neurons and enterochromaffin cells of the duodenum that does not cross the blood-brain barrier (Mann et al., 1992) . Thus, it is de facto a molecule with two functional identities depending on its site of synthesis. Whereas brain-derived serotonin is implicated in cognitive functions (Heath and Hen, 1995) , the function(s) of gut-derived serotonin (GDS), which accounts for 95% of total serotonin, is still a matter of debate (Gershon and Tack, 2007) . The GDS biosynthetic pathway involves the rate-limiting enzyme tryptophan hydroxylase 1 (Tph1). GDS is released in the general circulation, where most of it is taken up by platelets through a specific transporter (Gershon and Tack, 2007) . A small fraction of it, however, remains free in the serum and may conceivably act as a hormone following its binding to serotonin receptors present on target cells (Rand and Reid, 1951) . Remarkably, patients taking synthetic serotonin reuptake inhibitors (SSRIs) chronically, a class of drugs increasing extracellular serotonin concentration throughout the body, can have reduced bone mass (Richards et al., 2007) .
While searching for molecular mechanisms explaining Lrp5 regulation of bone formation, we identified Tph1 as the most highly overexpressed gene in Lrp5 À/À bones. Tph1 was also increased in Lrp5 À/À duodenal cells, its primary site of expression.
Inhibiting serotonin synthesis in Lrp5 À/À mice corrects their bone phenotype, and gut-but not osteoblast-specific deletion of Lrp5 recapitulates the bone phenotype of Lrp5 À/À mice. The same pathway is affected, in an opposite manner, in the case of Lrp5 gain-of-function mutation, thus providing a simple molecular basis for the two diseases. Serotonin, after binding to the Htr1b receptor, determines the extent of bone formation by controlling osteoblast proliferation through the regulation of CyclinD1 expression by CREB. By revealing that Lrp5 regulates bone mass by inhibiting duodenal synthesis of serotonin, a hormone decreasing bone formation, this study points toward adapted therapies for diseases characterized by an impairment of bone formation.
RESULTS

Molecular Signature of Lrp5 Loss-of-Function Mutation
The different nature of the cellular events leading to a low bone mass phenotype in Lrp5 À/À (decrease in bone formation) and b-Cat(ex3) osb À/À (decrease in bone resorption) mice suggested that distinct molecular mechanisms were at work in these two models. Thus, in an effort to elucidate how Lrp5 regulates bone formation, we looked for a specific molecular signature of Lrp5 loss-of-function mutation in bone in vivo. For that purpose, we analyzed the expression of genes affecting either cell proliferation (Cyclins), osteoblast differentiation (Runx2, Osx, Atf4), bone matrix deposition (Type I Collagen), or osteoclast differentiation (Osteoprotegerin, RankL) in wild-type, Lrp5
, and b-Cat(ex3) osb À/À bones. The only genes whose expression was decreased in Lrp5 À/À bones were the regulators of cell proliferation CycD1, D2, and E1 ( Figure 1A ). Consistent with the fact that osteoblast number is normal in b-Cat(ex3) osb À/À mice, expression of the Cyclin genes was not affected in b-Cat(ex3) osb À/À bones; conversely, genes whose expression was affected in b-Cat(ex3) osb À/À bones were normally expressed in Lrp5 À/À bones ( Figure 1A ). In striking contrast to the paucity of osteoblasts present in Lrp5 À/À bones (Kato et al., 2002) , Lrp5 À/À osteoblasts proliferated as well as WT cells ex vivo ( Figure 1B) . We interpreted the discrepancy between the in vivo and ex vivo proliferation abilities of the Lrp5 À/À osteoblasts as indicating that Lrp5 loss-offunction mutations affect osteoblast proliferation through extracellular signals that may not originate from osteoblasts, in other words that Lrp5-related bone diseases may not originate from bones.
As a first attempt to test the aforementioned hypothesis, we reanalyzed results of a microarray experiment performed earlier . The gene most highly expressed in Lrp5 À/À compared to WT bones was Tph1, which encodes an enzyme initiating synthesis outside the brain of serotonin, a secreted molecule that may affect bone mass (Warden et al., 2005) ( Figure 1C ). Real-time PCR analysis verified that Tph1 was overexpressed in Lrp5 À/À osteoblasts and bones ( Figure 1D ). Tph1 is predominantly expressed in duodenum in WT mice and it was also vastly overexpressed in this organ in Lrp5 À/À mice, where its expression was 1500-fold higher than in osteoblasts and 150-fold higher than in any other part of the gastrointestinal tract ( Figures 1E and 1F ). Tph1 expression was not affected in b-Cat(ex3) osb À/À bones, further differentiating Lrp5 and canonical Wnt signaling regulations of bone mass (see Figure S1A available online). In contrast, neither expression of Tph2, the enzyme initiating serotonin synthesis in the brain, nor brain serotonin content was affected in Lrp5 À/À mice (Figures S1B and S1C).
This latter observation is consistent with the notion that serotonin does not cross the blood-brain barrier (Mann et al., 1992) . Multiple correlative evidence suggested that this increase in Tph1 expression is implicated in the development of the Lrp5 À/À mice bone phenotype. First, Tph1 expression was normal in newborn Lrp5 À/À mice that do not display overt bone abnormalities but increased steadily thereafter ( Figures 1G, S1D , and S1E). A significant increase in Tph1 expression was first detected at 2 weeks of age, that is, 2 weeks before the low bone mass phenotype becomes apparent in Lrp5 À/À mice. Consistent with this increase in Tph1 expression, blood serotonin levels increased as a function of time in Lrp5 À/À mice ( Figure 1H ). This large increase in blood serotonin levels was not due to more platelets in Lrp5 À/À mice ( Figure S1F ). Second, Tph1 expression and blood serotonin levels were increased in Lrp5 +/À mice that also have a low bone mass ( Figures 1G and 1H ). Third, there was in three OPPG patients tested (Gong et al., 2001; Toomes et al., 2004 ) a 4-to 5-fold increase in circulating serotonin levels when compared to age-matched controls; moreover, the heterozygous parent of one of these patients also had higher circulating serotonin levels than control individuals ( Figures 1I and S1G Figure 2A ); in contrast, Wnt3A-conditioned media did not affect osteoblast proliferation ( Figure S2F ). Serotonin decreased expression of CycD1, D2, and E1 without affecting expression of Type I Collagen or of other genes characteristic of the osteoblast phenotype ( Figures 2B and S2A ), a gene expression profile remarkably similar to the one seen in the Lrp5 À/À bones ( Figure 1A ).
To further determine whether serotonin inhibits osteoblast proliferation in a Wnt-dependent or -independent manner, we treated ROS17 osteoblastic cells transfected with the TOPFLASH reporter construct with increasing amounts of serotonin or, as a positive control, with lithium chloride (LiCl) (Clement-Lacroix et al., 2005) . Whereas LiCl increased the activity of this reporter vector in all experiments, serotonin always failed to do so, indicating that the serotonin and canonical Wnt signaling pathways are distinct in osteoblasts ( Figure 2C ). If the increase in blood serotonin level is a cause of the Lrp5 À/À mice bone phenotype, then normalizing it should also normalize bone mass in these mice. To test this hypothesis, we performed two in vivo experiments. Because serotonin is a tryptophan derivative, we first fed WT and Lrp5 À/À mice from 3 to 12 weeks of age a diet containing 75% less tryptophan than a normal diet. (E and F) Real-time PCR analysis of Tph1 expression in tissues of WT and Lrp5 À/À mice (E), and in primary osteoblasts (Osb) and gut of WT mice (F).
(G and H) Real-time PCR analysis of Tph1 expression in gut versus bone (G), and serum serotonin levels (H) in WT, Lrp5
, and Lrp5 À/À mice at indicated ages.
(I) Serum serotonin levels in two OPPG patients and age-matched controls (n = 6).
Results are given as means ± standard deviations (SDs). Statistical analysis was performed by Student's t test. For all panels, *p < 0.05 and **p < 0.01 versus WT or control.
This reduction in tryptophan intake decreased circulating serotonin levels 8-to 10-fold without affecting serotonin brain content (Figures 2D and S2B) and normalized bone formation parameters and bone mass in Lrp5 À/À mice ( Figure 2E ). Second, 4-week-old WT and Lrp5 À/À mice were administered parachlorophenylalanine (pCPA), a drug inhibiting serotonin synthesis, for 8 weeks (Kubera et al., 2000) . pCPA decreased circulating serotonin levels 5-to 7-fold in Lrp5 À/À mice without affecting their serotonin brain content; it also normalized in Lrp5 À/À mice bone mass, bone formation parameters, and
Cyclin expression in bones . That pCPA did not induce regression of the hyaloid vessels in the eyes suggests that the eye phenotype of the Lrp5 À/À mice is not caused by this increase in circulating serotonin levels ( Figures S2D and S2E ). Taken together, results of the cell biology experiments of the low tryptophan diet and the pCPA-induced serotonin depletion in WT and Lrp5 À/À mice indicate that higher blood serotonin levels contribute to the decrease in bone formation and bone mass in Lrp5 À/À mice. Results are given as means ± SDs. Statistical analysis was performed by Student's t test. For all panels, *p < 0.05 and **p < 0.01 versus WT or control.
Lrp5 Regulates Serotonin Synthesis and Bone Formation through Its Duodenal Expression
In light of these results, we next asked whether Lrp5 regulates Tph1 expression, serotonin synthesis, and bone formation through its duodenal or its osteoblast expression. To that end, we generated mice harboring a floxed loss-of-function allele of Circulating serotonin levels were 5-to 8-fold higher in Lrp5 gut À/À than in WT mice but remained normal in Lrp5 osb À/À mice ( Figure 3C ). In both mutant mice, brain serotonin content was normal (data not shown).
Histomorphometric analyses showed a decrease in bone mass in Lrp5 gut À/À but not in Lrp5 osb À/À mice ( Figure 3D ). This low bone mass was secondary to a decrease in osteoblast numbers and bone formation whereas osteoclast numbers were not affected ( Figure 3D ). Expression of CycD1, D2, and E1 was decreased in the bones of Lrp5 gut À/À mice but was unaffected in Lrp5 osb À/À bones, and BrdU incorporation assays showed that osteoblast proliferation was decreased in Lrp5 gut À/À but not in Lrp5 osb À/À mice ( Figures 3E and 3F ). Thus, gut-but not osteoblast-specific deletion of Lrp5 recapitulates the low bone mass and the molecular abnormalities observed in the Lrp5 À/À mice. As is the case for Lrp5 +/À mice, Lrp5 gut +/À mice displayed a low bone formation/low bone mass phenotype ( Figure S3D ). These data suggest that Lrp5 regulates bone formation through its duodenal expression. In contrast, histological examination failed to detect any persistence of hyaloid vessels of the eyes in either Lrp5 gut À/À or Lrp5 osb À/À mice ( Figure S3E ). This latter result, along with the inability of pCPA to prevent appearance of the eye phenotype in the Lrp5 À/À mice, demonstrates that Lrp5 uses different mechanisms to regulate bone formation and eye vascularization.
Duodenal-Specific Lrp5-Activating Mutation Causes High Bone Mass
The demonstration that Lrp5 loss of function affects bone mass by enhancing serotonin synthesis in the enterochromaffin cells raised the prospect that, conversely, Lrp5 gain-of-function mutations might affect bone mass by decreasing serotonin synthesis in these cells. To test this hypothesis, we generated mice harboring a floxed allele of Lrp5 that included the mutation causing high bone mass in humans (Boyden et al., 2002) ). We studied heterozygous mutant mice because high bone mass syndrome is observed in patients heterozygous for the mutation (Boyden et al., 2002) .
Lrp5KI gut +/À mice expressed the mutated protein in gut but not in osteoblasts; the opposite was true for Lrp5KI osb +/À mice ( Figure 3G , S3H, and S3I). Tph1 expression in gut and circulating serotonin levels were low in Lrp5KI gut +/À mice ( Figures 3H and 3I) whereas serotonin content in the brain was not affected (data not shown). Histomorphometric analyses showed that bone formation parameters and bone mass were high in Lrp5KI gut +/À but normal in Lrp5KI osb +/À mice ( Figure 3D ). Expression of Cyclins and in vivo osteoblast proliferation were increased in Lrp5KI gut +/À bones; none of these parameters were modified in Lrp5KI osb +/À mice ( Figures 3J, 3K , and S3J). To validate our findings obtained in mice, we studied two patients with high bone mass caused by the same activating mutation (G171V) in LRP5 (Boyden et al., 2002) and observed a 50% decrease in circulating serotonin levels ( Figure 3L ). In summary, based on the analyses of cell-specific loss-and gain-of-function mutations of Lrp5 models, it appears that this gene regulates bone formation through its duodenal but not its bone expression.
Gut-Derived Serotonin Regulates Bone Formation
To further demonstrate that it is duodenal-derived serotonin that regulates bone formation, we generated mice harboring a floxed loss-of-function allele of Tph1 and crossed them with Villin-Cre or a 1 (I)Col-Cre mice to generate Tph1 gut À/À or Tph1 osb À/À mice ( Figures S4A-S4C ). Because Tph1 is overexpressed in Lrp5
mice, its deletion in the appropriate cell type should result in a bone phenotype opposite the one of the Lrp5 À/À mice (i.e., high bone mass). Tph1 gut À/À mice had a 10-fold reduction in Tph1 expression in gut, whereas Tph1 expression in bone and osteoblasts was not affected; conversely, Tph1 osb À/À mice had a 10-fold reduction in Tph1 expression in bones and osteoblasts but a normal Tph1 expression in gut ( Figures 4A and 4B ). Circulating serotonin levels were low in Tph1 gut À/À but normal in
Tph1 osb
À/À mice ( Figure 4C ). As anticipated, mice lacking Tph1 in the gut developed a severe high bone mass phenotype secondary to an increase in osteoblast number and bone formation rate; bone resorption parameters were not affected ( Figure 4D ). This phenotype, that is the mirror image of the one seen in the Lrp5 À/À mice, was present in 4-, 6-, and 12-week-old Tph1 gut À/À mice ( Figures 4D   and S4D ). In contrast, mice lacking Tph1 in osteoblasts had only a marginal, nonsignificant increase in bone mass ( Figure 4E ). Expression of CycD1, D2, and E1, which was decreased in the absence of Lrp5, was increased in Tph1 gut À/À but normal in Tph1 osb À/À bones, and BrdU incorporation assays showed that osteoblast proliferation was increased in Tph1 gut À/À but not in
À/À mice ( Figures 4F and 4G ).
The Htr1b Receptor Mediates Serotonin Regulation of Osteoblast Proliferation
If circulating serotonin is a hormone inhibiting bone formation, it must act through a specific receptor(s) present on osteoblasts whose inactivation should lead to an increase in bone formation and high bone mass. Among the 14 known serotonin receptors, only 3 are expressed in osteoblasts: Htr1b, the most highly expressed, Htr2b, and Htr2a ( Figure 5A ). Htr1b is preferentially expressed in bone and osteoblasts outside the brain, whereas Htr2b and Htr2a have a broader pattern of expression ( Figures 5B and  S5A) . Analysis of Htr2a À/À mice failed to detect any abnormalities in osteoblast number, bone formation, bone resorption, and bone mass at 1 or 3 months of age ( Figures 5C and S5B ), two time points at which Lrp5 À/À mice already display a severe bone phenotype. The same was true for mice lacking in osteoblasts only, Htr2b ( Figures 5D and S5B-S5E ). In contrast, mice lacking either one or the two Htr1b alleles displayed a similar increase in osteoblast number, bone formation rate, and bone mass at those ages ( Figures 5E and S5B) . That haploinsufficiency at Htr1b has consequences as severe as the homozygous deletion, at least at 6 weeks of age, is consistent with the fact that heterozygous loss-of-function mutation in Tph1 or heterozygous gain-of-function mutation in Lrp5 also have consequences as severe on bone mass as homozygous mutations. Furthermore, it is also in accord with the observation that patients with high bone mass are only heterozygous for Lrp5 mutations. Altogether, it demonstrates that loss of serotonin signaling exerts a dominant function on bone remodeling. Figure 5H ). Other osteoblastspecific genes such as Osteoprotegerin, a Wnt target gene , were normally expressed in Htr1b À/À bones, further differentiating canonical Wnt and serotonin signaling pathways in osteoblasts ( Figure S5F ).
To ascertain that Htr1b regulates bone formation through its expression in osteoblasts, we generated mice lacking Htr1b only in osteoblasts (Htr1b osb -deficient mice; Figures S5G and S5H). As shown in Figure 5I , Htr1b osb +/À mice display the same high bone formation/high bone mass phenotype as the one observed in the Htr1b +/À mice. Taken together, these results indicate that serotonin uses one predominant receptor, Htr1b, to affect osteoblast biology.
Serotonin Regulates Osteoblast Proliferation through CREB
We next searched for the transcriptional mediator(s) of serotonin signaling in osteoblasts. To address this question, because lossof-function mutations in most of the key transcription factors governing osteoblast differentiation are embryonic lethal, we generated compound mutant mice lacking one allele of Lrp5 and one allele of each transcription factor of interest. We reasoned that if Lrp5 and a particular transcription factor are in the same genetic cascade, compound heterozygous mice may reproduce the bone phenotype of the Lrp5 À/À mice. Removing one allele of Runx2 or Osx from Lrp5 +/À mice did not worsen the bone phenotype of these latter mutant mice, a result consis- , and Tph1 osb À/À mice.
Results are given as means ± SDs. Statistical analysis was performed by Student's t test. For all panels, *p < 0.05 and **p < 0.01 versus WT or control.
tent with the normal expression of Runx2 and Osx in Lrp5 À/À osteoblasts ( Figure 1A ). These observations strongly suggest that neither of these two factors act downstream of serotonin ( Figures 6A  and S6 ). Because Htr1b is linked to the Gai protein that inhibits cAMP production and PKA-dependent phosphorylation (Heath and Hen, 1995) , we studied transcription factors that, like CREB, are phosphorylated by PKA. Removing one allele of Atf4, a CREB-related osteoblast-enriched transcription factor , from Lrp5 +/À mice did not affect the bone phenotype of these latter mice, arguing against a role for ATF4 in mediating serotonin signaling in osteoblasts ( Figures 6A and  S6 ). In contrast, compound mutant mice lacking one allele of Lrp5 and, in osteoblasts only, one allele of Creb displayed a low bone formation/low bone mass phenotype indistinguishable from the one observed in the Lrp5 À/À mice ( Figures 6A and S6 ). This result suggested that CREB is a major transcriptional mediator of serotonin signaling in osteoblasts. In support of this contention, serotonin treatment of primary osteoblasts decreased phosphorylation of CREB on Ser133, the target of PKA, in WT but not in Htr1b À/À cells ( Figure 6B ) and abolished binding of CREB to the promoter of CycD1, a known target gene of CREB ( Figure 6C ) (Fu et al., 2005) . That CycD1 expression is decreased in Creb osb +/À but not in Atf4 +/À mice, used here as a negative control, is in full agreement with the ex vivo assays presented above ( Figure 6D ). Furthermore, that Creb expression was decreased in Lrp5 gut À/À long bones, increased in Lrp5KI gut +/À long bones, but unaffected in either Lrp5 osb À/À or Lrp5KI osb +/À long bones ( Figure 6E ) raises the prospect that serotonin regulates Creb expression in vivo.
Genetic Validation of the Interactions between Lrp5, Tph1, Htr1b, and Creb To demonstrate that the gut-derived serotonin/osteoblast/CREB pathway described here mediates Lrp5-dependent regulation of osteoblast proliferation and bone formation, we generated various compound mutant mice. First, we showed that mutant mice lacking one allele of Htr1b and one allele of Tph1 in gut cells developed the same high bone mass phenotype as Htr1b À/À or Tph1 gut À/À mice ( Figures 7A and S7A) . Moreover, removal of one allele of Creb, in an osteoblast-specific manner, from the Htr1b À/À mice rescued the increase in bone formation parameters and the high bone mass of these mutant mice ( Figures 7A and S7A) . These experiments indicated that Tph1 in gut cells, and Htr1b and Creb in osteoblasts, are in the same genetic cascade regulating bone formation. Next, to ascertain that Tph1 in the gut and Htr1b mediate Lrp5-dependent regulation of bone mass, we removed from the Lrp5 À/À mice one allele of Tph1 in gut cells or one allele of Htr1b ( Figures 7A and S7A ). Both these manipulations could normalize the bone abnormalities observed in the Lrp5 À/À mice, indicating that serotonin synthesis in duodenal enterochromaffin cells and serotonin binding to Htr1b are downstream of Lrp5 ( Figures 7A and S7A) . Thus, the results presented in this study indicate that the main mechanism whereby Lrp5 favors bone formation and bone mass accrual is by inhibiting Tph1 expression in and serotonin synthesis by enterochromaffin cells of the gut. Serotonin in turn prevents bone formation following its binding to Htr1b by inhibiting Creb expression and function, CycD1 expression, and osteoblast proliferation. Results are given as means ± SDs. Statistical analysis was performed by Student's t test. For all panels, *p < 0.05 and **p < 0.01 versus WT or control.
Lrp5 and b-Cat Expression in Gut and Bone Mass
Because Lrp5 has been proposed to be a Wnt coreceptor, we next asked whether it was regulating Tph1 expression in a b-Cat-dependent or -independent manner. To that end, we generated mice lacking one allele of Lrp5 and one allele of b-Cat in gut cells ( Figures S7B and S7C ), reasoning that if Lrp5 and b-Cat were in the same genetic pathway then these compound heterozygous mice should have the same low bone formation and low bone mass phenotype as the Lrp5 À/À mice.
This strategy has been used by us to demonstrate genetic interaction between b-Cat and other genes in osteoblasts . As shown in Figure 7B , whereas Lrp5 +/À mice had a low bone formation and low bone mass phenotype, b-Cat gut +/À mice did not; more importantly, the compound heterozygous Lrp5 +/À ; b-Cat gut +/À did not have a more severe low bone formation and low bone mass than the Lrp5 +/À mice. Molecularly, there was no change in Tph1 expression in the gut and in serum serotonin levels in b-Cat gut +/À compared to WT mice ( Figure 7C ). We also generated compound mutant mice lacking one allele of Tph1 and one allele of b-Cat in gut. Here again, we did not see in Tph1 gut
;b-Cat gut +/À any worsening of the bone phenotype observed in the Tph1 gut +/À mice ( Figure 7B ). Because of their negative nature, these results have to be interpreted cautiously, yet that b-Cat haploinsufficiency can in other cell types lead to phenotypic abnormalities strongly suggests that Lrp5 regulates Tph1 expression and serotonin synthesis independently of b-Cat expression in gut .
Decreasing Duodenal Serotonin Synthesis Protects
Mice from Ovariectomy-Induced Bone Loss To assess the biological importance of the serotonin regulation of bone mass, we tested whether the increase in bone formation parameters observed in Tph1 gut À/À mice was sufficient to protect them from ovariectomy-induced bone loss. WT and Tph1 gut À/À were ovariectomized (Ovx) at 6 weeks of age and analyzed at 3 months of age. Histomorphometric analyses showed an increase in bone resorption parameters in both WT and Tph1 gut À/À mice following Ovx ( Figure 7D ). Nevertheless, whereas Ovx WT mice developed a low bone mass phenotype, Ovx Tph1 gut À/À mice still harbored a high bone mass phenotype which was due to their increase in bone formation parameters ( Figure 7D ). Thus, decreasing serotonin production in enterochromaffin cells of the gut protects mice from ovariectomyinduced osteoporosis.
DISCUSSION
This study uncovers an unanticipated molecular mechanism accounting for the Lrp5 regulation of bone formation; our findings Results are given as means ± SDs. Statistical analysis was performed by Student's t test. For all panels, *p < 0.05 and **p < 0.01 versus WT or control.
shift the emphasis from a paracrine to an endocrine regulation of bone mass, and from bone cells to enterochromaffin cells of the gut ( Figure 7E ). Moreover, given the cell-specific expression of Tph1, this study points toward novel therapeutic avenues for diseases characterized by a relative or absolute decrease in bone formation.
Lrp5-Dependent Serotonin Synthesis in the Gut and Regulation of Bone Formation
Regardless of the mode of action of Lrp5, a hallmark of Lrp5
bones is a paucity of osteoblasts, a feature contrasting strikingly with the fact that Lrp5 À/À osteoblasts proliferate normally ex vivo. One possible explanation of this discrepancy could be that osteoblast proliferation in the Lrp5 À/À mice is affected by an extracellular signal that is not originating from osteoblasts themselves.
In full support of the hypothesis that the extracellular signal regulating osteoblast proliferation in the absence of Lrp5 does not emanate from osteoblasts, cell-specific gene inactivation or gain-of-function studies established that it is through its expression in enterochromaffin cells of the gut and not through its expression in osteoblasts that Lrp5 controls Tph1 expression, serotonin synthesis, osteoblast proliferation, and bone formation. The differences in the severity of the bone phenotype observed in Tph1 gut À/À and Lrp5KI gut +/À mice raises the hypothesis that Lrp5 regulates expression in enterochromaffin cells of other gene(s) regulating bone mass. Last, we cannot rule out that Lrp5 may exert an autocrine function in osteoblasts that was not detectable in the genetic manipulations performed here. By showing that OPPG and high bone mass syndrome are more gut-than bone-originating diseases, these results put new light on these two conditions. This work does provide an explanation for the osteoporosis often observed in patients with autism who have high blood serotonin levels (Hediger et al., 2008) ; however, it does not explain why patients taking SSRIs chronically often develop osteoporosis (Richards et al., 2007) .
LRPs, Bone Remodeling, and Canonical Wnt Signaling Lrp5 is a member of the family of lipoprotein receptor related proteins (Lrps), a small group of single-pass transmembrane proteins (Tamai et al., 2000) . Lrp5 has a significant degree of sequence homology with the Drosophila protein Arrow, a Wingless coreceptor (Pinson et al., 2000; Tamai et al., 2004) . Based on this sequence homology and multiple forced expression experiments in cell culture and in vivo, it has been assumed that Lrp5 is a coreceptor for Wnt proteins, the mammalian homologs of Wingless, and that it is in this capacity that it regulates bone formation (Gong et al., 2001; Kato et al., 2002) . However, at the present time, all in vivo evidence available indicates that Lrp5 regulates gut-derived serotonin production and bone formation in a canonical Wnt signaling pathway-independent manner. First, expression of classical Wnt target genes is normal in Lrp5 À/À mice gut ( Figure S7D) ; second, serotonin does not affect the activity of a TOPFLASH reporter construct or the expression of Osteoprotegerin in osteoblasts, nor does it affect osteoclast differentiation as b-Cat inactivation does (Basselin et al., 2005) . The homology of Arrow with Lrp5 extends to other Lrp proteins. Indeed, the closest Lrp5 relative, Lrp6, also has a high degree of homology with Arrow. This is important, because all genetic evidence obtained before the function of Lrp5 during bone formation was discovered suggested that Lrp6 was a better candidate than Lrp5 to be a Wnt coreceptor. For instance, Lrp6 but not Lrp5 is required for Wnt signaling in Xenopus and in mice (Pinson et al., 2000; Tamai et al., 2004; Wehrli et al., 2000) . Likewise, Wnt proteins fused to Frizzled could interact with Lrp6 but not with Lrp5 to activate a Wntresponsive reporter gene (Holmen et al., 2002) , Lrp6 inactivation affects embryonic development whereas Lrp5 inactivation does not (Pinson et al., 2000) , and, more decisively, Lrp6 inactivation affects bone resorption in a TCF-dependent manner like b-Cat osteoblast-specific inactivation does but does not impair bone formation as Lrp5 loss-of-function mutation does Kato et al., 2002; Kubota et al., 2008) .
Our results do not rule out, however, that Lrp5, in other organs and/or in cell types other than osteoblasts, may transduce a Wnt signal. In particular, that the eye phenotype of the Lrp5 À/À mice is not observed in the case of a duodenal-and osteoblast-specific deletion of Lrp5 and is not corrected by decreasing extracellular serotonin concentration rules out a serotonin involvement in this abnormality. This observation provides indirect support to previous work showing an involvement of Lrp5 in Wnt signaling in that case (Lobov et al., 2005) .
Serotonin Signaling in Osteoblasts
Three serotonin receptors are expressed in osteoblasts. Two of them, Htr2b and Htr2a, are broadly expressed whereas Htr1b is, outside the brain, a fairly osteoblast-enriched gene. According to gene deletion experiments, Htr1b is the receptor responsible for the effect of serotonin on osteoblasts, whereas inactivation of either Htr2b or Htr2a does not affect bone mass. Our results regarding Htr2b are different from those of Collet et al. (2008) . However, in their case, the bone phenotype was observed in mice lacking the gene in all cells, whereas in our case Htr2b was deleted only in osteoblasts. Thus, our results relate more tightly to the function (or lack) of this gene in osteoblasts. It is possible that the low bone mass phenotype they noted in the classical Htr2b À/À mice could be secondary to the decrease in heart function observed in these mice (Nebigil et al., 2000) . Until recently, the prevailing view of the transcriptional control of osteoblast biology is that it involves one of three players that are osteoblast specific: Runx2, Osx, and ATF4. Yet, none of these three transcription factors appears implicated in serotonin signaling in osteoblasts. Instead, CREB, a factor already known to affect osteoblast proliferation but that is broadly expressed (Fu et al., 2005) , is the main transcriptional effector of serotonin signaling in osteoblasts. This observation, along with the emerging role in osteoblasts of other transcription factors such as, among others, Schnurri-3 or FOXO that are not osteoblast specific (Jones et al., 2006; Manolagas and Almeida, 2007) , suggest that besides cell-specific transcription factors, other ones, more broadly expressed, will influence significantly differentiation and/ or functions of the osteoblasts.
The demonstration that Lrp5 belongs to a novel endocrine axis regulating bone formation illustrates the power of an integrative approach to bone physiology. It also raises additional questions. For instance and from a biological point of view, we do not know yet how Lrp5 expression affects Tph1 expression in enterochromaffin cells of the gut. The structure of the Lrp5 protein raises the prospect that it may be a signaling receptor for a yet to be identified serotonin synthesis-inhibiting molecule. From a therapeutic point of view, the fact that ovariectomized Tph1 gut À/À mice do not display bone loss holds great promise given Tph1 cell-specific expression. Further experiments will be needed to determine whether pharmacologically inhibiting Tph1 or use of a selective peripheral Htr1b receptor antagonist(s) is a valid approach in the treatment of postmenopausal osteoporosis.
EXPERIMENTAL PROCEDURES Mice Generation
To generate osteoblast-specific and gut-specific gene-deficient mice for Lrp5, Tph1, and Lrp5KI mutations and Htr2b (osb , Osx À/À , Villin-Cre, and a 1 (I)Col-Cre mice was previously reported (Dacquin et al., 2002; el Marjou et al., 2004; Glass et al., 2005; Heath and Hen, 1995; Kato et al., 2002; Mantamadiotis et al., 2002; Weisstaub et al., 2006; Yang et al., 2004) .
Histology, Protein Expression, and Proliferation Assays Immunohistochemistry was performed according to standard protocols on specimens embedded in paraffin and sectioned at 6 mm (Ducy et al., 2000) . In vivo osteoblast proliferation assays (Zymed Laboratories) were performed on 4-week-old mice injected with BrdU (0.4 mg) and sacrificed 4 hr later. Static and dynamic histomorphometric analyses were performed on vertebral column specimens collected from 3-month-old mice using undecalcified sections according to standard protocols using the Osteomeasure analysis system (Osteometrics). Six to 12 animals were analyzed for each group.
Cell Cultures and Bioassays
Primary osteoblasts were cultured as previously described (Ducy et al., 2000) . Drug treatments were performed in 0.1% FBS. Cell proliferation was quantified by BrdU or MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assays (Kato et al., 2002) . Serum serotonin levels were quantified by ELISA (serotonin kit, Fitzgerald), whereas serotonin levels in brain regions were quantified by HPLC as described previously (Mann et al., 1992) .
Molecular Studies
RNA isolation and real-time PCR was performed following standard protocols. Genotypes of all the mice were determined by PCR (see Figures S3-S5 ). All primer sequences are available upon request.
Statistical Analysis
Results are given as means ± standard deviations. Statistical analysis was performed by Student's t test. For Figures 1-7 and S1-S6, *p < 0.05 and **p < 0.01 versus WT or control.
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